Larissa Bergin

Jones Day (Washington DC)
Lawyer (Associate)

Larissa Bergin’s practice addresses the antitrust concerns arising from M&A matters, joint ventures, federal investigations, and commercial practices. She has overseen the antitrust aspects of corporate M&A, including due diligence, risk-shift negotiations, Hart-Scott-Rodino (HSR) filings, Second Requests, investigational hearings, integration planning, and consent decrees with federal agencies. She works with clients in a variety of industries, including the technology, health care, retail, and pharmaceutical sectors. Many of Larissa’s clients have international reach, and she has been involved in matters that require advocacy before governments throughout Asia, the EU, and North America.

Distinctions

Linked authors

Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (San Francisco)

Articles

203 Bulletin

Jonathan Berman, Rosanna McCalips, Julia McEvoy, Larissa Bergin The U.S. Congress implements a new law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities (Patient Right to Know Drug Prices Act)

77

New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar (...)

Send a message